These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 30979460)

  • 1. Randomized, Open-Label, Phase IV, Korean Study of Kidney Transplant Patients Converting From Cyclosporine to Prolonged-Release Tacrolimus Plus Standard- or Reduced-Dose Corticosteroids.
    Baek CH; Kim CD; Lee DR; Kim YH; Yang J; Kim BS; Lee JS; Han SY; Kim SW; Lee S; Lee KW; Kong JM; Shin BC; Lee SH; Chae DW; Kwon YJ; Jiang H; Lee H; Park SK
    Transplant Proc; 2019 Apr; 51(3):749-760. PubMed ID: 30979460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of Posttransplantation Diabetes Mellitus in De Novo Kidney Transplant Recipients Receiving Prolonged-Release Tacrolimus-Based Immunosuppression With 2 Different Corticosteroid Minimization Strategies: ADVANCE, A Randomized Controlled Trial.
    Mourad G; Glyda M; Albano L; Viklický O; Merville P; Tydén G; Mourad M; Lõhmus A; Witzke O; Christiaans MHL; Brown MW; Undre N; Kazeem G; Kuypers DRJ;
    Transplantation; 2017 Aug; 101(8):1924-1934. PubMed ID: 27547871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Effectiveness of Conversion From Cyclosporine to Once-Daily Prolonged-Release Tacrolimus in Stable Kidney Transplant Patients: A Multicenter Observational Study in Japan.
    Usuki S; Uno S; Sugamori H; Tanaka H; Aikawa A
    Transplant Proc; 2018 Dec; 50(10):3266-3274. PubMed ID: 30577196
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ADHERE: randomized controlled trial comparing renal function in de novo kidney transplant recipients receiving prolonged-release tacrolimus plus mycophenolate mofetil or sirolimus.
    Rummo OO; Carmellini M; Rostaing L; Oberbauer R; Christiaans MH; Mousson C; Langer RM; Citterio F; Charpentier B; Brown M; Kazeem G; Lehner F;
    Transpl Int; 2017 Jan; 30(1):83-95. PubMed ID: 27754567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and Effectiveness of Once-Daily, Prolonged-Release Tacrolimus in De Novo Kidney Transplant Recipients: 5-year, Multicenter Postmarketing Surveillance in Japan.
    Wakasugi N; Uchida H; Uno S
    Transplant Proc; 2018 Dec; 50(10):3296-3305. PubMed ID: 30577199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of adherence and tolerability of prolonged-release tacrolimus (Advagraf™) in kidney transplant patients in Germany: A multicenter, noninterventional study.
    Lehner LJ; Reinke P; Hörstrup JH; Rath T; Suwelack B; Krämer BK; Budde K; Banas B
    Clin Transplant; 2018 Jan; 32(1):. PubMed ID: 29052906
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adherence of Renal Transplant Recipients to Once-daily, Prolonged-Release and Twice-daily, Immediate-release Tacrolimus-based Regimens in a Real-life Setting in Sweden.
    Fellström B; Holmdahl J; Sundvall N; Cockburn E; Kilany S; Wennberg L
    Transplant Proc; 2018 Dec; 50(10):3275-3282. PubMed ID: 30577197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical Study of Standard- vs Reduced-Dose Tacrolimus Combined With Generic Mycophenolate Mofetil in De Novo Kidney Transplantation: A Prospective Randomized Trial.
    Bang JB; Oh CK; Ju MK; Kim SJ; Yu HC; Lee SH
    Transplant Proc; 2020; 52(1):133-139. PubMed ID: 31898939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical experience of conversion from cyclosporine to tacrolimus prolonged-release in stabilized kidney transplant patients.
    Krejci K; Zadrazil J; Lackova E; Zilinska Z; Roland R; Dedinska I
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2016 Sep; 160(3):407-11. PubMed ID: 27174195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
    Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
    Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Delayed Prolonged-Release Tacrolimus Initiation in De Novo Hepatitis C Virus-Negative Orthotopic Liver Transplant Recipients: A Single-Center, Single-Arm, Prospective Study.
    Lladó L; González-Castillo A; Fabregat J; Baliellas C; Ramos E; González-Vilatarsana E; Busquets J; Xiol X
    Ann Transplant; 2019 Jan; 24():36-44. PubMed ID: 30655498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
    Gruessner RW
    Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Corticosteroid avoidance in adult kidney transplant recipients under rabbit anti-T-lymphocyte globulin, mycophenolate mofetil and delayed cyclosporine microemulsion introduction.
    Cantarovich D; Rostaing L; Kamar N; Saint-Hillier Y; Ducloux D; Mourad G; Garrigue V; Wolf P; Ellero B; Cassuto E; Albano L; Soulillou JP;
    Transpl Int; 2010 Mar; 23(3):313-24. PubMed ID: 19843296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy and safety of cyclosporine reduction in de novo renal allograft patients receiving sirolimus and corticosteroids: results from an open-label comparative study.
    Mühlbacher F; Neumayer HH; del Castillo D; Stefoni S; Zygmunt AJ; Budde K;
    Transpl Int; 2014 Feb; 27(2):176-86. PubMed ID: 24266855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Tacrolimus Trough Level Is Reflected by Estimated Glomerular Filtration Rate (eGFR) Changes in Stable Renal Transplantation Recipients: Results of the OPTIMUM Phase 3 Randomized Controlled Study.
    Park S; Kim YS; Lee J; Huh W; Yang CW; Kim YL; Kim YH; Kim JK; Oh CK; Park SK
    Ann Transplant; 2018 Jun; 23():401-411. PubMed ID: 29891834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
    Ekberg H; Bernasconi C; Nöldeke J; Yussim A; Mjörnstedt L; Erken U; Ketteler M; Navrátil P
    Nephrol Dial Transplant; 2010 Jun; 25(6):2004-10. PubMed ID: 20106825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion.
    Filler G; Webb NJ; Milford DV; Watson AR; Gellermann J; Tyden G; Grenda R; Vondrak K; Hughes D; Offner G; Griebel M; Brekke IB; McGraw M; Balzar E; Friman S; Trompeter R
    Pediatr Transplant; 2005 Aug; 9(4):498-503. PubMed ID: 16048603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
    Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
    Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose mizoribine combined with calcineurin inhibitor (cyclosporine or tacrolimus), basiliximab and corticosteroids for renal transplantation: A Japanese multicenter study.
    Nishioka T; Yoshimura N; Ushigome H; Watarai Y; Nishimura K; Akioka K; Nakamura N; Kawakita M; Yuzawa K; Nakatani T
    Int J Urol; 2018 Feb; 25(2):141-145. PubMed ID: 29068092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal Function and Patient-Reported Outcomes in Stable Kidney Transplant Patients Following Conversion From Twice-Daily Immediate-Release Tacrolimus to Once-Daily Prolonged-Release Tacrolimus: A 12-Month Observational Study in Routine Clinical Practice in Germany (ADAGIO).
    Hugo C; Weihprecht H; Banas B; Schröppel B; Jank S; Arns W; Schenker P; Rath T; Hergesell O; Feldkamp T; Hermann B; Schiffer M
    Transplant Proc; 2021 Jun; 53(5):1484-1493. PubMed ID: 33610306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.